The European Head and Neck Society (EHNS) today announces European-wide ‘Early Diagnosis Days’ taking place on Wednesday 24 September as part of this year’s Head and Neck Cancer Awareness Week (22–26 September). This follows the success of the 2013 campaign, where nearly 100 ‘Early Diagnosis Days’ took place. More than 5,000 patients were seen by a healthcare provider in 1 day, resulting in a referral rate of approximately 5% and multiple diagnoses of the disease.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762527-EHNS-early-diagnosis-days/
In partnership with Men’s Health Network (MHN), Prostate Health Education Network (PHEN), ZERO – the End of Prostate Cancer and Joe Torre, four-time world champion baseball Hall-of-Famer and prostate cancer survivor, Genomic Health, Inc. (Nasdaq: GHDX) today launched Your Prostate Your Decision to educate prostate cancer patients and their loved ones that every man is different and every cancer is unique, and a genomic test can clarify the aggressiveness of one’s disease prior to invasive treatment. This first-of-its-kind national effort aims to address concerning results of a large national survey that found low general awareness about prostate cancer aggressiveness and treatment options, underscoring the need for better understanding of active surveillance as a treatment plan.
“For a man with prostate cancer, a single decision can change his entire life,” said Mr. Torre, reflecting on his own experience with prostate cancer. “When I was diagnosed with prostate cancer, I faced a game-changing decision. While I chose surgery, a less aggressive approach called active surveillance might be the best choice.”
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7322251-your-prostate-your-decision-joe-torre-talks-about-prostate-cancer-genomic-testing-treatment-options-psa/
Friends since 1988, Sheryl Crow and Melissa Etheridge have endured their share of hardships—bad breakups, depression and for Etheridge, the anxiety around coming out sexually. But they fought their toughest battle when, within two years of each other, Crow and Etheridge each received a breast cancer diagnosis, shaking their worlds to the core. Through sheer determination and perseverance, they came out the other side. Now healthy and happy, the two survivors sat down with AARP The Magazine to discuss what they've learned and how they've each found a renewed sense of self.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7334451-aarp-the-magazine-music-legends-sheryl-crow-and-melissa-etheridge-talk-about-beating-cancer/
Hologic, Inc. (NASDAQ: HOLX) is kicking off Breast Cancer Awareness Month with the announcement that the Company's groundbreaking 3D mammography exam, available on the Selenia Dimensions platform, will be introduced to consumers today as Genius 3D Mammography. Hologic’s Genius 3D Mammography is the only 3D exam approved by the FDA as clinically superior to traditional mammography.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7254155-hologic-new-consumer-awareness-campaign-mammography-technology/
Understanding the burden of metastatic breast cancer (MBC), and the toll it takes on patients and their loved ones, Eisai Inc. announced today the launch of mbcInfoCenter.com, a new online portal designed to provide important resources that may help women with MBC manage their disease and focus on their health and wellness.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7342251-eisai-launches-mbc-infocenter-for-women-with-metastatic-breast-cancer/
Janssen-Cilag International NV (Janssen) announced today that the European Commission has approved IMBRUVICA™ (ibrutinib) capsules, a first-in-class, once-daily, oral Bruton’s tyrosine kinase (BTK) inhibitor. This new approach to treating blood cancers works by blocking BTK, a protein that helps certain cancer cells live and grow.1 IMBRUVICA is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), or adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762540-janssen-ec-approval-imbruvica-mcl-cll/
BloodCenter of Wisconsin’s Diagnostic Laboratories today announced the availability of a comprehensive cancer mutation HemeOnc Panel using next generation sequencing (NGS) technology. The NGS panel developed by BloodCenter of Wisconsin is designed to detect variants in 30 genes that are either prognostic or diagnostic for 10 different myeloid hematologic malignancies.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7363151-bloodcenter-of-wisconsin-launches-next-generation-sequencing-hemeonc-panel/
Significant advances toward cures for blood cancer patients, many of which were funded by The Leukemia & Lymphoma Society (LLS) over the past 65 years, are among the dramatic highlights featured in Ken Burns presents CANCER: THE EMPEROR OF ALL MALADIES, a film by Barak Goodman, to air on PBS stations nationwide from March 30-April 1. The documentary series is based on the Pulitzer Prize-winning book by Siddhartha Mukherjee, MD, The Emperor of All Maladies: A Biography of Cancer.
LLS has been a driving force behind treatment breakthroughs for patients with blood cancers, including leukemia, lymphoma and myeloma. As the world’s largest voluntary health agency dedicated to finding cures for blood cancer patients, LLS has invested more than $1billion in research to advance lifesaving treatments and cures.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7409151-lls-cancer-research-pbs-series/
Every three minutes someone in the U.S. is diagnosed with a blood cancer. No one knows this better than “Nashville” star Charles Esten and his wife Patty. Esten’s 15-year-old daughter, Addie, was diagnosed with leukemia at age 2 ½. Naturally, their world was turned upside down. But, they quickly learned that there was hope, based on research to advance new treatments and cures for leukemia, much of it funded by The Leukemia & Lymphoma Society (LLS).
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7491051-charles-esten-light-the-night-walks/
Currently melanoma is the deadliest form of skin cancer and one of the most common cancers in women under 40 years old in the United States. The first line of defense in helping to reduce the risk of developing melanoma is by wearing broad spectrum UVA and UVB SPF protection. L’Oréal Paris, a leading global beauty brand, and Melanoma Research Alliance (MRA), the leading private funder of melanoma research, announced today the launch of It’s THAT Worth It To Me. This social media campaign encourages women to donate 15 social media seconds by sharing why SPF protection or using sunless tanner is worth it to protect their skin, their beauty and their life. For every social share, L’Oréal Paris will donate $1 to MRA to fund the L’Oréal Paris - MRA Team Science Award Research Grant, up to $250,000 in 2015.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7459051-l-oreal-paris-mra-it-s-that-worth-it/
Today, the American Lung Association's LUNG FORCE initiative is joining forces with Academy Award®-nominated actress, Laura Dern, country music star Kellie Pickler, and Emmy- and Golden Globe-winning actress, Valerie Harper, during National Women’s Lung Health Week (May 10th -16th) to share their voices in an effort to defeat lung cancer in women.
Every eight minutes, a woman in the United States dies of lung cancer. It is the #1 cancer killer of women, killing almost twice as many women as any other cancer. Yet, awareness is extremely low. Only 1 percent of women cite lung cancer as a women’s cancer that is top-of-mind for them, according to the American Lung Association's Women's Lung Health Barometer. Now in its second year, LUNG FORCE, in partnership with national presenting sponsor, CVS Health, is empowering women and men everywhere to share their voices and make lung cancer a public health priority.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7521751-ala-lung-force-cancer-women/
Evidence from the Childhood Cancer Survivor Study suggests that changes in childhood cancer treatment have reduced deaths from the late effects of cancer treatment and extended the lives of childhood cancer survivors. St. Jude Children’s Research Hospital investigators led the research, which will be presented today at the plenary session of the 2015 annual meeting of the American Society of Clinical Oncology (ASCO).
The study is one of four being featured at the plenary session press briefing, which highlights research that ASCO deems as having the highest scientific merit and greatest potential to affect patient care.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7532851-st-jude-cancer-research/
